Health Report 08-9

合集下载

Bora-Care说明书

Bora-Care说明书

SAFETY DATA SHEETHealth Emergencies: INFOTRAC® (800) 535-50531. PRODUCT AND COMPANY INFORMATIONProduct Identity:Bora-Care®Recommended use of the chemical and restrictions on use:Termiticide, Insecticide, and Fungicide Concentrate. Read andunderstand the entire label before using. Use only according to labeldirections. It is a violation of Federal law to use this product in amanner inconsistent to label directions.Manufacturer:Nisus Corporation100 Nisus DriveRockford, TN 37853Telephone:Phone: (800) 264-0870Fax: (865) 577-5825Emergency Phone: 800-535-5053 (INFOTRAC)SDS Date of Preparation: 08/05/162. HAZARDS IDENTIFICATIONGHS Classification:Physical Health Environmen tNot Hazardous Acute Toxicity Oral Category 4Specific Target Organ Toxicity –Repeat Exposure Category 2Reproductive Toxicity Category 2AquaticAcuteToxicityCategory 3GHS Label Elements:Statements of HazardH302 Harmful if swallowed.H361 Suspected of damaging fertility or the unborn child.H373 May cause damage to kidneys by prolonged or repeated exposure by ingestion.H412 Harmful to aquatic life with long lasting effects.Precautionary StatementsP260 Do not breathe mist or vapors.P264 Wash thoroughly after handling.P270 Do not eat, drink, or smoke when using this product.P273 Avoid release to the environment.P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor if you feel unwell.P330 Rinse mouth.P501 Dispose of contents and container in accordance with local and national regulations.3. COMPOSITION/INFORMATION ON INGREDIENTSComponent CAS No. AmountEthylene Glycol107-21-140-60%Disodium OctaborateTetrahydrate12280-03-4 40%Non-Hazardous Ingredient Proprietary 0-20%The exact formulation is being withheld as a trade secret.4. FIRST AID MEASURESEye: Flush victim's eyes with large quantities of water, while holding the eyelids apart. Get medical attention if irritation develops or persists. Skin: Wash skin thoroughly with soap and water. Get medical attention if irritation develops. Remove and launder clothing beforere-use.Ingestion: Do not induce vomiting unless directed to do so by a medical professional. Get immediate medical attention for large ingestions or if symptoms develop or if you feel unwell.Inhalation: Remove victim to fresh air. If breathing is difficult or irritation persists, get medical attention.Most important Symptoms: May cause eye and skin irritation. Inhalation of mists may cause mild mucous membrane and respiratory irritation. Harmful if swallowed. Repeated ingestion may cause kidney damage.Indication of immediate medical attention/special treatment: Immediate medical attention is required for large ingestions.5. FIRE FIGHTING MEASURESSuitable (and Unsuitable) Extinguishing Media: Use media appropriate for surrounding fire. Cool fire exposed containers and structures with water.Specific hazards arising from the chemical: A solid stream of water or foam directed into hot, burning liquids can cause frothing. Burning may product carbon monoxide, carbon dioxide, and ethylene oxide.Special Protective Equipment and Precautions for Fire-Fighting Instructions: Firefighters should wear positive pressure self-contained breathing apparatus and full protective clothing. Contain all runoff.6. ACCIDENTAL RELEASE MEASURESPersonal Precautions, Protective Equipment, and Emergency Procedures: Evacuate spill area and keep unprotected personnel away. Wear appropriate protective clothing as described in Section 8. Avoid releases to the environment.Methods and Materials for Containment and Cleaning Up: Dike and collect liquid or absorb with an inert absorbent and place in appropriate containers for disposal. Prevent spill from entering sewers and watercourses. Report releases as required by local, state and federal authorities.7. HANDLING AND STORAGEPrecautions for Safe Handling: Avoid contact with the eyes, skin and clothing. Avoid breathing mists or aerosols. Wear protective clothing and equipment as described in Section 8. Use with adequate ventilation. Wash thoroughly with soap and water after handling. Remove contaminated clothing immediately and wash before reuse. Remove PPE immediately after handling. Wash thoroughly after using and change into clean clothing. Keep containers closed when not in use.Nonrefillable container. Do not reuse containers. Product residues in empty containers can be hazardous. Follow all SDS precautions when handling empty containers.Conditions for Safe Storage, Including Any Incompatibilities: Store in a cool, dry, well-ventilated area away from incompatible materials. Keep out of reach of children. Do not freeze. Protect from physical damage.8. EXPOSURE CONTROLS/PERSONAL PROTECTIONExposure Guidelines:Ethylene Glycol 100 mg/m3 Ceiling ACGIH TLVDisodium Octaborate Tetrahydrate 2 mg/m3 TWA ACGIH TLV (Inhalable) 6 mg/m3 STEL ACGIH TLV (Inhalable)Engineering Controls: Use with adequate general or local exhaust ventilation to maintain exposure levels below the occupational exposure limits.Respiratory Protection: In operations where exposure levels are exceeded, a NIOSH approved respirator with dust/mist cartridges with approved pesticide prefilter or supplied air respirator appropriate for the form and concentration of the contaminants should be used. Selection and use of respiratory equipment must be in accordance with OSHA 1910.134 and good industrial hygiene practice. Refer to the product label for additional information.Skin Protection: Wear impervious gloves such as butyl rubber, nitrile, neoprene, polyethylene, polyvinyl chloride, or Viton. Follow instructions for Category C on an EPA resistance category selection chart for more options.Eye Protection: Wear safety goggles or glasses where splashing is possible.Other:Wear long-sleeve shirts, long pants, socks and shoes when using this product. Suitable washing facilities should be available in the work area.9. PHYSICAL AND CHEMICAL PROPERTIESAppearance And Odor: Clear viscous gel with no odor.Physical State: Viscous gel Odor Threshold: Not established Vapor Density: Not determinedInitial Boiling Point/Range: >212°F (>100°C )Solubility In Water: Soluble Vapor Pressure: Negligible Relative Density: 1.38 Evaporation Rate: Not determined Melting/Freezing Point: Not determinedpH: 6.9-7.1 (50% solution in water)Percent Volatile: 36% by weight as waterOctanol/Water Coefficient: Not determinedSolubility: Soluble in waterDecomposition Temperature: Not determinedViscosity: 8000-11,000 centipoise at room temperatureFlammability (solid, gas): N/AFlashpoint: >220°F (104°C) TOC Autoignition Temperature: None Flammable Limits: LEL: Not determined UEL: Not determined 10. STABILITY AND REACTIVITYReactivity: Not normally reactiveChemical Stability: Stable under normal storage and handling conditions.Possibility of Hazardous Reactions: None known.Conditions to Avoid: None known.Incompatible Materials: Avoid strong oxidizing agents and aluminum. Hazardous Decomposition Products: When heated to decomposition emits carbon monoxide, carbon dioxide, and ethylene oxide.11. TOXICOLOGICAL INFORMATIONHEALTH HAZARDS:Ingestion: Harmful if swallowed. Repeated or high levels of ingestion may cause potentially fatal kidney damage.Inhalation: Inhalation of mists may cause irritation of the nose, throat and upper respiratory tract.Eye: May cause slight irritation with redness, pain and tearing. Product was not irritating in a study with rabbits.Skin: May cause irritation on prolonged or repeated contact. Product was not irritating in a study with rabbits. Negative in a guinea pig sensitization study.Chronic: Ethylene glycol causes kidney damage through repeated ingestion.Sensitization: This material is not known to cause sensitization. Carcinogenicity: None of the components is listed as a carcinogen or suspected carcinogen by IARC, NTP or OSHA.Germ Cell Mutagenicity: No data availableReproductive Toxicity: Ethylene glycol has been found to cause birth defects in laboratory animals. The significance of this finding to humans has not been determined.Numerical Measures of Toxicity:Product Toxicity Data:Oral rat LD50: >5000 mg/kg; Dermal rabbit LC50: >5050 mg/kg; Inhalation rat LC50: >5.06 mg/L (no mortality was observed in any test) Component Toxicity Data:Ethylene Glycol: Oral rat LD50: 4700 mg/kg; Dermal rabbit LC50:9530 mg/kg Disodium Octaborate Tetrahydrate: Oral rat LD50: 3500-4100 mg/kg; Dermal rabbit LD50: >2000 mg/kg; Inhalation rat LC50: >2.0 mg/L12. ECOLOGICAL INFORMATIONEcotoxicity:Ethylene Glycol: LC50 Fathead Minnow: <10,000 mg/L/96 hr.; EC50 Daphnia Magna: 100,000 mg/L/48 hr; Bacterial (Pseudomonas putida): 10,000 mg/l; Protozoa (Entosiphon sulcatum and Uronema parduczi; Chatton-Lwoff): >10,000 mg/l; Algae (Microcystis aeruginosa): 2,000 mg/l; Green Algae (Scenedesmus quandricauda): >10,000 mg/l Disodium Octaborate Tetrahydrate: EC10 Green Algae: 24 mg B/L/96 hr; LC50Daphnia Magna: 133 mg B/L/48 hr; NOEC-LOEC Daphnia Magna: 6-13 mg B/L/21-day; LC50Limanda limanda: 74 mg B/L/96 hr; LC50 Rainbow Trout: 150 mg B/L/24-day, 100 mg B/L/32-day; LC50 Goldfish: 46 mg B/L/7-day, 178 mg B/L/3-dayThis product is classified as harmful to the aquatic environment. Releases to the environment should be avoided.Persistence and Degradability: Ethylene glycol is readily biodegradable (97-100% in 2-12 days). Boron is naturally occurring and ubiquitous in the environment. Disodium Octaborate Tetrahydrate degrades to boron.Bioaccumulative Potential: Ethylene glycol: A BF of 10 reported for ethylene glycol in fish, Golden ide (Leuciscus idus melanotus), after 3 days of exposure suggests the potential for bio concentration in aquatic organisms is low. Disodium Octaborate Tetrahydrate: Log K ow: -0.7570 at 25°C.Mobility in Soil: Disodium Octaborate Tetrahydrate is soluble in water and is leachable through normal soil.Other Adverse Effects: Some plants are sensitive to boron. Avoid releases into the environment. This product is designed to be used for certain types of wood destroying insects. Use product only as directed on the label. Avoid all unintended releases and releases to ground water. Do not apply to water or to intertidal areas where surface water is present or to intertidal areas below the mean high water mark. Do not contaminate water when cleaning equipment or disposing of equipment washwaters. See product label for full instructions and restrictions on use.13. DISPOSAL CONSIDERATIONDispose in accordance with local, state and federal environmental regulations. Do not contaminate water when disposing of washwaters. Do not discharge effluent containing this product into lakes, streams, ponds, estuaries, ocean, or other water unless in accordance with the requirements of a National Pollutant Discharge Elimination System (NPDES) permit and the permitting authority has been notified in writing prior to discharge. Do not discharge effluent containing this product to sewer systems without previously notifying the local sewage treatment plant authority. For guidance contact your state water board or regional office of the EPA.14. TRANSPORTATION INFORMATIONDOT Hazardous Materials Description: Not Regulated (unless package contains a reportable quantity)Note: If a shipment of a reportable quantity (10,000 lbs/870 gal) in a single package is involved, the following information applies:Proper Shipping Name: RQ, Environmentally hazardous substance, liquid, n.o.s. (Ethylene glycol)UN Number: UN3082Hazard Class/Packing Group: 9, IIILabels Required: Class 9IATA: Not RegulatedIMDG: Not Regulated15. REGULATORY INFORMATIONThis chemical is a pesticide product registered by the United States Environmental Protection Agency and is subject to certain labeling requirements under federal pesticide law. These requirements differ from the classification criteria and hazard information required for safety data sheets (SDS), and for workplace labels of non-pesticide chemicals. The hazard information required on the pesticide label is reproduced below. The pesticide label also includes other important information, including directions for use.FIFRA Labeling:Bora-CareEPA Reg. No. 64405-1Keep Out of Reach of ChildrenCAUTIONPRECAUTIONARY STATEMENTSHazards to Humans & Domestic AnimalsPRECAUTIONARY STATEMENTSWear long sleeved shirt & long pants, socks, shoes and chemical resistant gloves (such as Barrier Laminate, Butyl Rubber, Nitrile Rubber, Neoprene Rubber, Polyvinyl Chloride (PVC), Viton or others listed in Category C on an EPA chemical resistance category selection chart).CERCLA: This product has a reportable quantity (RQ) of 10,000 lbs based on the RQ for ethylene glycol of 5,000 lbs present at 40-50%. Some states have more stringent reporting requirements. Report all spills in accordance with local, state, and federal regulations.SARA Hazard Category (311/312): Acute Health, Chronic Health SARA 313: This product contains the following chemicals subject to Annual Release Reporting Requirements Under SARA Title III, Section 313 (40 CFR 372):Ethylene Glycol 107-21-1 40-50%EPA TSCA Inventory: This product is regulated under FIFRA, thus exempt.16. OTHER INFORMATIONNFPA Rating:Health = 2 Flammability = 1 Instability = 0HMIS Rating:Health = 2 Flammability = 1 Physical Hazard = 0 SDS Revision History: 11/01/03: New SDS08/05/16: RevisedWARRANTY DISCLAIMERThe information, data and recommendations contained herein are believed to be accurate but may not be all inclusive and should only be used as a guide. The information is furnished upon the condition that the person receiving it shall make his own determination of the suitability of the product for his particular use and on condition that they assume the risk of the use thereof. With respect to this publication and the product related thereto, unless otherwise expressly provided by Manufacturer in writing, MANUFACTURER MAKES NO EXPRESS OR IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER EXPRESS OR IMPLIED WARRANTY.Remedy/Liability LimitsThe exclusive remedy for losses or damages resulting from this publication or the related product (including claims based on contract, negligence, strict liability or other legal theories) shall be limited to, at Manufacturer’s sole election, one of the following:1. Refund of purchase price paid by buyer or user for productbought, or2. Replacement of amount of product used.Manufacturer shall not be liable for losses or damages resulting from use of this publication or handling or use of this product, IN NO CASE SHALL MANUFACTURER BE LIABLE FOR CONSEQUENTIAL OR INCIDENTAL DAMAGES OR LOSSES, INCLUDING WITHOUT LIMIT, HEALTH RELATED DAMAGES OR INJURIES.The terms of this Warranty Disclaimer and Remedy/Liability Limits cannot be varied by any written or verbal statements or agreements. No employee or sales agent of Manufacturer or the seller is authorized to vary or exceed the terms of this Warranty Disclaimer or Limitation of Remedies in any manner.100 Nisus Drive • Rockford, TN 37853 USA • (800) 264-0870Bora-Care and Nisus Corporation are registered trademarks of Nisus Corporation. ©2020 Nisus Corporation• #BC-SDS-080516a。

QbD理念在药品质量控制中的应用

QbD理念在药品质量控制中的应用

1QbD 的概念QbD 源于英文quality by design 的缩写[1,2]。

在美国,QbD 是cGMP 的最基本成分,是正确的、基于风险的、充分的、积极的新药开发途径[3]。

QbD 的理念是通过实验设计(DOE),找出影响质量的关键属性参数,建立设计空间(DesignSpace)[4]。

通过科学的验证,对设计空间不断进行改进,最终建立稳健的控制空间[5]。

近些年,随着人力及物料成本的不断上升[6,7],导致药品成本不断提高,药品安全事件层出不穷[8-10]。

QbD 理念的实施,对于提高中国药品的研发水平及药品的质量有很大的帮助[11-13]。

2QBD 理念的变迁过程质量的概念经历过三个阶段,QbT (质量源于检验)、QbP(质量源于生产)、QbD(质量源于设计)。

在QbT 理念时期,在药品生产过程中,人们认为产品质量的好坏是由检验决定的,但是检验仅仅是一种事后行为,并且检验抽取的仅是个别样品,并不足以代表所有样品。

而在药品研发过程中,杂质的控制更多也只是依靠检验,并没有将精力更多的投入到处方工艺的筛选及验证中。

同样,药品分析方法的验证多数是在分析方法已经开发完成后,即方法后期对其验证,此时验证,仅仅只能考察单因素对分析方法的影响,而多个因素的交互作用则完全不被考察,因此,在面对多个变量时,分析方法的稳健性不足以被保证。

在QbP 理念时期,人们意识到检验结果不能完全代表产品的好坏,唯有稳定的生产工艺才是产品质量的保证。

但是若处方在开发阶段就没有经历科学的筛选,充分的优化以及严格的验证,在药品生产过程中仍不足以应对所有变数。

不能完全保证生产出合格的产品。

而在QbD 理念阶段,人们已经意识到,产品的质量控制点应前移至产品开发阶段,在开发阶段找出影响产品质量的关键参数并且充分验证,可以保证应对未来发生的风险,在源头对产品质量进行控制。

而分析方法的开发同样如此,将控制放在方法初期,在初期就对关键质量参数进行筛选和验证,从而保证开发出稳健的分析方法。

健康报告英语作文100

健康报告英语作文100

健康报告英语作文100英文回答:Health Report.Personal Information.Name: [Your Name]Age: [Your Age]Gender: [Your Gender]Height: [Your Height]Weight: [Your Weight]Blood Type: [Your Blood Type]Medical History.Allergies: [List any allergies]Past Illnesses: [List any past illnesses]Surgeries: [List any surgeries you have had]Medications: [List any medications you are currently taking]Lifestyle Factors.Smoking: [Indicate whether you smoke or not]Alcohol Consumption: [Indicate how much alcohol you consume, if any]Drug Use: [Indicate whether you use any drugs or not]Exercise: [Indicate how much exercise you get]Diet: [Describe your diet]Sleep: [Indicate how much sleep you get]Current Health Status.Physical Examination.Blood Pressure: [Your blood pressure reading] Heart Rate: [Your heart rate]Respiratory Rate: [Your respiratory rate]Temperature: [Your temperature]Skin: [Describe the condition of your skin] Eyes: [Describe the condition of your eyes] Ears: [Describe the condition of your ears] Nose: [Describe the condition of your nose]Throat: [Describe the condition of your throat]Lymph Nodes: [Describe the condition of your lymph nodes]Musculoskeletal System: [Describe the condition of your musculoskeletal system]Neurological System: [Describe the condition of your neurological system]Laboratory Tests.Complete Blood Count: [Results of your complete blood count]Comprehensive Metabolic Panel: [Results of your comprehensive metabolic panel]Lipid Panel: [Results of your lipid panel]Urinalysis: [Results of your urinalysis]Imaging Studies.Chest X-ray: [Results of your chest X-ray]Abdominal Ultrasound: [Results of your abdominal ultrasound]Health Assessment.Overall, your health is [good/fair/poor].You are at [low/moderate/high] risk for [list any health risks].Recommendations.[List any recommendations for improving your health]中文回答:健康报告。

中华医学会系列期刊参考文献著录格式要求(2008)

中华医学会系列期刊参考文献著录格式要求(2008)

中华医学会系列期刊参考文献著录格式要求(2008)中华医学会系列期刊参考文献著录格式(2006年8月修订)中华医学会系列期刊参考文献的著录格式,基本参照执行GB/T 7714-2005《文后参考文献著录规则》,采用顺序编码制。

1 文内引用参考文献的标注采用顺序编码制,即按文献出现的先后顺序用阿拉伯数字连续编码,并将序号置于方括号中。

可根据具体情况分别按下述3种格式之一标注。

1.薛社普等[1]指出棉酚从体内排泄缓慢。

2.麦胶敏感性肠病的发病有3种机制参与[2,4-6]。

3.间质细胞cAMP含量测定方法见文献[7]。

正文指明原始文献作者姓名时,序号标注于作者姓名之后(如例1);正文未指明作者或非原始文献作者时,序号标注于句未(如例2);正文直接述及文献序号时,不用角码标注(如例3)。

标注应尽可能靠近有关引文,写在标点符号之前。

如引文在全句之末,其中句号在引号之内,则应标注在引号之外(“……。

”[x]);否则应标注在句号之内(“……”[x]。

)。

图中引用参考文献,按其在全文中出现的顺序编号,序号标注写在图的说明或注释中,图中不应出现引文序号标注。

表中引用参考文献,按其在全文中出现的顺序编号,在表注中依次标注;若必须在表身中标注,在表中单列一栏说明文献来源,该栏应列出文献第一作者姓名,在姓名右上角标注文献角码。

2 文后参考文献表参考文献应采用小于正文的字号,排印在正文之后。

“参考文献”字样可以左顶格排,句末不用“:”;也可以居中排。

同一种期刊体例应一致。

文后参考文献表中的各篇文献应按文中引文的顺序左顶格依次排列,序号一律用阿拉伯数字,加方括号,与正文中的序号格式一致,序号后空一字。

只有1条参考文献时,序号写为1。

著录文字原则上要求用原文献文字,除版次、期号、册次、页数、出版年等数字用阿拉伯数字表示外,均应保持文献原有的形式。

每条文献著录项目应齐全,不得用“同上”或“ibid”表示。

同一文献作者不超过3人,全部著录;超过3人,可以只著录前3人,后依文种加表示“,等”的文字(如西文加“,et al”,日文加“,他”)。

超实用高考英语专题复习:专题 08---定语从句专题(含高考真题)

超实用高考英语专题复习:专题 08---定语从句专题(含高考真题)

超实用高考英语专题复习:专题08定语从句专题距离高考还有一段时间,不少有经验的老师都会提醒考生,愈是临近高考,能否咬紧牙关、学会自我调节,态度是否主动积极,安排是否科学合理,能不能保持良好的心态、以饱满的情绪迎接挑战,其效果往往大不一样。

以下是本人从事10多年教学经验总结出的以下学习资料,希望可以帮助大家提高答题的正确率,希望对你有所帮助,有志者事竟成!养成良好的答题习惯,是决定高考英语成败的决定性因素之一。

做题前,要认真阅读题目要求、题干和选项,并对答案内容作出合理预测;答题时,切忌跟着感觉走,最好按照题目序号来做,不会的或存在疑问的,要做好标记,要善于发现,找到题目的题眼所在,规范答题,书写工整;答题完毕时,要认真检查,查漏补缺,纠正错误。

总之,在最后的复习阶段,学生们不要加大练习量。

在这个时候,学生要尽快找到适合自己的答题方式,最重要的是以平常心去面对考试。

英语最后的复习要树立信心,考试的时候遇到难题要想“别人也难”,遇到容易的则要想“细心审题”。

越到最后,考生越要回归基础,单词最好再梳理一遍,这样有利于提高阅读理解的效率。

另附高考复习方法和考前30天冲刺复习方法。

【课前练习】(4minutes)一.单句语法填空1.[2020全国Ⅲ,61]In ancient China lived an artist________ paintings were almost lifelike.2.[2020江苏,21]Many lessons are now available online,from___________students can choose for free.3.[2019 天津,11]Their child is at the stage _________she can say individual words but not full sentences.4.[2018 全国I,66]Two of the authors of the review also made a study published in 2014_______showed a mere five to 10 minutes a day of running reduced the risk of heart disease and early deaths from all causes.5.[2018浙江,57]Many westerners___________come to China cook much less than in their own countries once they realize how cheap it can be to eat out.6.[2017乙卷(全国I),70]Like anything, it is possible to have too much of both,__________is not good for the health.二.单句填空1.Yesterday she sold her car,__she bought a month ago.A.whomB.whereC. thatD.which2.We will put off the picnic in the park until next week._the weather may be better.A.thatB.whereC.whichD.when3.I walked in our garden,_Tom and Jim were tying a big sign onto one of the trees.A.whichB.whenC.whereD. that4.The settlement is home to nearly 1,000 people, many of________left their village homes for a better life in the city. A.whom B.which C.them D.those5.Gun control is a subject____Americans have argued for a long time.A.of whichB.with whichC. about whichD.into which三.划出下列句子中的定语从句1.The exact year which Angela and her family spent together in China was 2008.(2019安徽)2.Among the many dangers, which sailors have to face, probably the greatest of all is fog.(2014江西)一.判断定语从句1.识别和划出定语从句(1)识别定语a clever/handsome boy the polluted water fallen leavesthe cat behind the door the girl standing under the tree stories in the Long March二.概念定语从句:在复合句中起形容词作用,作定语,修饰名词或代询的从句叫定语从句。

SM:与同性发生性关系的男性:The Once and Future HIV ...

SM:与同性发生性关系的男性:The Once and Future HIV ...
(from Tim Brown) (作者:Tim Brown)
Proportion new infections by population in Thailand 泰国新艾滋病感染者各种人群比例 1.0
0.8
Asian Epidemic Model 亚洲流行病模型
MSM projected to soon be the predominant population for HIV/AIDS cases in Thailand 预计与同性发生 性关系的男性不 久之后将成为泰 国艾滋病病毒/艾 国艾滋病病毒 艾 滋病感染病例的 主要人群
San Francisco, 1981 1981 年旧金山 Los Angeles, 1981 1981 年洛杉矶
1981 Europe (France) 1981 年欧洲(法国) 年欧洲(法国)
1984 Asia (Thailand) 1984 年亚洲(泰国) 年亚洲(泰国)
1980 Middle East (retrospectively) 1980 年中东(回顾) 年中东(回顾) Africa’s first HIV cases doubted because not MSM! 非洲首例艾滋病病毒感 染病例怀疑并非男性与 同性发生性关系所致! 同性发生性关系所致!
Prevalence (%) 盛行率 (%)
% MSM of adults 成年艾滋病感染者中与同性发生性关系的男性比例
So what? 现状如何? 现状如何?
HIV is now predominantly heterosexually transmitted in the world … and among women 艾滋病病毒在全世界…以及女性中间通过异性恋 艾滋病病毒在全世界 以及女性中间通过异性恋 大肆传播

高考英语语法词汇专项突破:08非谓语动词短文填空专练(含高考真题) (原卷板)

高考英语语法词汇专项突破:08非谓语动词短文填空专练(含高考真题) (原卷板)

高考英语语法词汇专项突破:08非谓语动词短文填空专练(No.9-12)+答案卡(原卷板)(素材来源:高考真题、教材原文、知名网站、权威考题等)姓名:__________ 班级: _________ 限时:45分钟得分:____________养成良好的答题习惯,是决定高考英语成败的决定性因素之一。

做题前,要认真阅读题目要求、题干和选项,并对答案内容作出合理预测;答题时,切忌跟着感觉走,最好按照题目序号来做,不会的或存在疑问的,要做好标记,要善于发现,找到题目的题眼所在,规范答题,书写工整;答题完毕时,要认真检查,查漏补缺,纠正错误。

第三组:(No.9-12)No.9阅读下面短文,在空白处填入括号内单词的正确形式。

Xiao long bao(soup dumplings), those ___1____ (amaze) constructions of delicate dumpling wrappers, encasing hot, tasty soup and sweet, fresh meat, are far and away my favorite Chinese street food. The dumplingsarrive ___2___ (steam) and dangerously hot. To eat one, youhave to decide whether ___3__ (bite) a small hole in it first,releasing the stream and ____4__ (risk) a spill (溢出), or to putthe whole dumpling in your mouth, letting the hot soup explodeon your tongue. Shanghai may be the ___5___ (recognize) homeof the soup dumplings but food historians will actually point youto the neighboring canal town of Nanxiang as Xiao long Bao’sbirthplace. There you will find them ___6____ (prepare)differently---- more dumpling and less soup, and the wrappers are pressed by hand rather than ____7____ (roll) . Nanxiang aside, the best Xiao long bao have a fine skin, allowing them ___8____ (lift) out of the steamer basket without __9___ (tear) or spilling any of their contents. The meat should be fresh with a touch of sweetness and the soup hot, clear and delicious.No matter where I buy them, one steamer is rarely enough, yet two seems greedy, so I am always left ____10____ (want) more next time. (209 words) 【改编自(普通高等学校招生全国统一考试2023年新课标全国Ⅰ卷) 】No.10阅读下面短文,在空白处填入括号内单词的正确形式。

健康报告英文作文

健康报告英文作文

健康报告英文作文英文:Health Report。

I have always been conscious about my health and make sure to maintain a healthy lifestyle. I exercise regularly, eat a balanced diet, and get enough rest. As a result, I have a good overall health condition.I believe that exercise is the key to a healthy body. I usually go for a run or do some yoga in the morning, and I also enjoy playing sports with friends on the weekends. Exercise not only helps me stay fit, but it also boosts my mood and reduces stress.In terms of diet, I try to eat a variety of fruits, vegetables, whole grains, and lean protein. I also limit my intake of processed foods and sugary drinks. I find that cooking my own meals at home allows me to control theingredients and ensure that I am eating healthily.Getting enough rest is also crucial for my health. I make sure to get at least 7-8 hours of sleep every night, and I avoid using electronics before bedtime to help me relax.Overall, I believe that taking care of my physical and mental health is essential for a happy and fulfilling life.中文:健康报告。

COC Document Checklist-R8

COC Document Checklist-R8

系統稽核所需之文件(中國)The Document Checklist (China)—Revised 08請提供以下記錄供審核員參考❑ 1. 工卡或考勤記錄 (過去十二個月已發放工資的月份開始計算),如果使用电子考勤,审核员需要在电脑里直接抽查审阅考勤记录,审阅会是在工厂职员协助下进行。

Timecards or Attendance Records (Last 12 Months starting from the most recent paying month) ,If electronic time card is used, Auditor needs review the attendance record directly from the computer, with the assistance with factory staff.❑ 2. 工資表 (過去十二個月已發放工資的月份開始計算)Payroll Records for Paid Wages (Last 12 months starting from the most recent paying month)❑ 3. 人事花名冊及員工個人檔案,勞動合同Personnel Records, Labor Contract❑ 4. 商标许可合同Trademark Contract Agreement❑ 5. 社會保險收據、花名冊及合格證明文件等Receipt, Name List and Certificate of Social Insurance, Etc.❑ 6. 工商營業執照, 工厂组织架构图Business Registration, Factory Organization Chart❑7. 建筑工程消防验收意见书或消防檢查報告或合格証明文件Fire Safety Inspection or Certificate❑8. 消防演習記錄、緊急疏散预案、消防逃生图、义务消防员培训记录及工傷記錄等Fire Drill Record, Emergency Evacuation Plan, Evacuation floor Plan, Fire Training, Work Accident Records and Work-related Injury Record❑9. 環保證明文件( 环境影响评估报告,排污许可证,生产及医疗废物处理记录等)Environmental Certificate (Environment Impact evaluation report, Waste Discharge Approval Certificate,Dangerous Waste and Medical Waste Disposal Record)□ 10. 化学品使用及个人防护用品使用培训记录, 职业病体检报告Chemical and PPE Usage Training & Occupation health examination report❑11. 车间空气质量 & 噪音检测报告Workshop air quality & noise level inspection report❑12. 廠規或員工手冊, 禁止使用童工政策,禁止使用强迫劳动,体罚,歧视政策。

ICH指导原则文件目录(中英文)

ICH指导原则文件目录(中英文)

ICH指导原则文件目录(中英文)人用药品注册技术要求国际协调会(ICH)文件目录ICH的论题主要分为四类,因此ICH根据论题的类别不同而进行相应的编码分类:1. “Q”类论题:Q代表QUALITY,指那些与化工和医药,质量保证方面的相关的论题。

Q1/Q2...Q10都属于这类。

2. “S”类论题:S代表SAFETY,指那些与实验室和动物实验,临床前研究方面的相关的论题。

3. “E”类论题:E代表EFFICACY,指那些与人类临床研究相关的课题。

4. “M”类论题:M代表MULTIDISCIPLINARY, 指那些不可单独划入以上三个分类的交叉涉及的论题。

同时M又细分为5个小类:M1: 常用医学名词(Med DRA)M2: 药政信息传递之电子标准M3: 与临床试验相关的临床前研究时间的安排M4: 常规技术文件(CTD)M5: 药物词典的数据要素和标准一、ICH. 质量部分(Quality)稳定性1.Quality质量2.Q1: Stability稳定性3.Q1A(R2): Stability Testing of New Drug Substances and Products 新原料药和制剂的稳定性试验4.Q1B: Photostability Testing of New Drug Substances and Products 新原料药和制剂的光稳定性试验5.Q1C: Stability Testing for New Dosage Forms 新剂型的稳定性试验6.Q1D: Bracketing and Matrixing Designs for Stability Testing of Drug Substances and Drug Products原料药和制剂稳定性试验的交叉和矩阵设计 Q1E: Evaluation of Stability Data 稳定性数据的评估7.Q1F: Stability Data Package for Registration Applications in Climatic Zones III andIV在气候带III和IV,药物注册申请所提供的稳定性数据8.Q2: Analytical Validation分析验证9.Q2(R1): Validation of Analytical Procedures: Text and Methodology分析程序的验证:正文及方法论10.Q3: Impurities 杂质11.Q3A(R2): Impurities in New Drug Substances 新原料药中的杂质12.Q3B(R2): Impurities in New Drug Products (Revised Guideline) 新制剂中的杂质13.Q3C(R3): Impurities: Guideline for Residual Solvents 杂质:残留溶剂指南Impurities: Guideline for Residual Solvents (Maintenance) 杂质:残留溶剂指南(保留)PDE for Tetrahydrofuran (in Q3C(R3)) 四氢呋喃的日允许接触剂量PDE for N-Methylpyrrolidone (in Q3C(R3)) N-甲基吡咯烷酮的日允许接触剂量14.Q4: Pharmacopoeias药典15.Q4A: Pharmacopoeial Harmonisation 药典的协调16.Q4B: Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions药典内容的评估及推荐为用于ICH地区17.Q4B Annex1 Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regionson Residue on Ignition/Sulphated Ash General Chapter附录1 药典内容的评估及推荐为用于ICH地区关于灼烧残渣/灰分常规篇18.Q4B Annex2 Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regionson Test for Extractable Volume of Parenteral Preparations General Chapter附录2 药典内容的评估及推荐为用于ICH地区关于注射剂可提取容量测试常规篇19.Q4B Annex3 Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regionson Test for Particulate Contamination: Sub-Visible Particles General Chapter附录3 药典内容的评估及推荐为用于ICH地区关于颗粒污染物测试:不溶性微粒常规篇20.Q5: Quality of Biotechnological Products 生物技术制品质量21.Q5A(R1): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin来源于人或者动物细胞系的生物技术产品的病毒安全性评估22.Q5B: Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived ProteinProducts生物技术产品的质量:源于重组DNA的蛋白质产品的生产中所用的细胞中的表达构建分析23.Q5C: Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products生物技术产品的质量:生物技术/生物产品的稳定性试验24.Q5D: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products用于生产生物技术/生物产品的细胞底物的起源和特征描述25.Q5E: Comparability of Biotechnological/Biological Products Subject to Changes inTheir Manufacturing Process基于不同生产工艺的生物技术产品/生物产品的可比较性26.Q6: Specifications规格27.Q6A: Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances (including decision trees) 质量规格:新原料药和新制剂的检验程序和可接收标准:化学物质(包括决定过程)28.Q6B: Specifications: Test Procedures and Acceptance Criteria for29.Biotechnological/Biological Products质量规格:生物技术/生物产品的检验程序和可接收标准30.Q7: Good Manufacturing Practices (GMP)31.Q7A: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients活性药物成份的GMP指南32.Q8: Pharmaceutical Development药物研发33.Annex to Q8Q8附录34.Q9: Quality Risk Management质量风险管理35.Q10: Pharmaceutical Quality System药物质量体系二、ICH.安全性部分(Safety) 致癌试验1.S1A Guideline on the Need for Carcinogenicity Studies of Pharmaceuticals 药物致癌试验的必要性2.S1B Testing for Carcinogenicity of Pharmaceuticals 药物致癌试验3.S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals药物致癌试验的剂量选择4.S1C’药物致癌试验的剂量选择的附件:补充剂量限度和有关注释遗传毒性5.S2(R1) Guidance on Genotoxicity Testing and Data Interpretation forPharmaceuticals Intended for Human Use 人用药物的遗传毒性试验和数据分析指导原则6.S2A药物审评遗传毒性试验的特殊性指导原则7.S2B遗传毒性:药物遗传毒性试验标准组合药代8.S3A Note for Guidance on T oxicokinetics: The Assessment of Systemic Exposurein Toxicity Studies 毒代动力学指导原则:毒性研究中全身暴露的评价9.S3B Pharmacokinetics: Guidance for Repeated Dose TissueDistribution Studies药代动力学:重复给药的组织分布研究指导原则慢性毒性10.S4Duration of Chronic T oxicity Testing in Animals (Rodent and Non RodentToxicity Testing) 动物慢性毒性试验的周期(啮齿类和非啮齿类)生殖毒性11.S5(R2) Detection of T oxicity to Reproduction for Medicinal Products andToxicity to Male Fertility (the Addendum dated November 1995 has beenincorporated into the core guideline in November 2005 )12.S5A药品的生殖毒性检测13.S5B雄性生育力毒性其他14.S6Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals 生物技术药品的临床前安全性试验15.S7A Safety Pharmacology Studies for Human Pharmaceuticals 人用药物的安全性药理研究16.S7B The Non-clinical Evaluation of the Potential for Delayed VentricularRepolarization (QT Interval Prolongation) by Human Pharmaceuticals人用药延迟心室复极化(QT间期延长)潜在作用的非临床评价指导原则17.S8Immunotoxicity Studies for Human Pharmaceuticals人类药品的免疫毒性研究18.S9 Nonclinical Evaluation for Anticancer Pharmaceuticals 抗癌药物的临床前评价19.S10 Photosafety Evaluation三、ICH.临床部分(Efficacy)1.E1The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-T erm Treatment of Non-Life-Threatening Conditions 评价临床长期给药方案的安全性2.E2A Definitions and Standards for Expedited Reporting 快速报告的定义和标准3.E2B(R3) Data Elements for Transmission of Individual Case Safety Reports个体病例安全性报告传递的数据要素4.E2C Periodic Benefit-Risk Evaluation Report 上市药品定期安全性更新报告5.E2D Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting批准后安全性数据管理:快速报告的定义和标准6.E2E Pharmacovigilance Planning药物警戒计划7. E2F Development Safety Update Report8.E3Structure and Content of Clinical Study Reports 临床研究报告的结构与内容9.E4Dose-Response Information to Support Drug Registration 新药注册所需量-效关系的资料10.E5(R1)Ethnic Factors in the Acceptability of Foreign Clinical Data 对国外临床研究资料的种族因素的可接受性11.E6(R1) Good Clinical Practice: Consolidated Guideline 药品临床研究规范(GCP)一致性指导原则12.E7Studies in Support of Special Populations: Geriatrics 老年人群的临床研究13.E8General Considerations for Clinical Trials 临床试验的一般考虑14.E9Statistical Principles for Clinical Trials 临床试验统计原则15.E10Choice of Control Group and Related Issues in Clinical Trials 对照组的选择16.E11Clinical Investigation of Medicinal Products in the Pediatric Population 儿童人群的临床研究17.E12按治疗分类的各类药物临床评价E12 Principles for Clinical Evaluation of New Antihypertensive Drugs18.E14The Clinical Evaluation of QT/QT c Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs 非抗心律失常药物致QT/QT c间期延长及潜在心律失常作用的临床评价19.E15 Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories20.E16 Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure and Format of Qualification Submissions四、ICH.综合部分 (Multidisciplinary)1.M1医学术语Med DRA2.M2Electronic Transmission of Individual Case Safety Reports MessageSpecification (ICH ICSR DTD Version 2.1) companion document to E2B(R3)注册资料传递所需的电子代码3.M3Guidance on Nonclinical Safety Studies for the Conduct of Human ClinicalTrials and Marketing Authorization for Pharmaceuticals与临床研究有关的临床前研究的时间安排4.M4 Organisation of the Common Technical Document for the Registration ofPharmaceuticals for Human Use (Edited with Numbering and Section Header Changes, September 2002). Including the Annex : the Granularity Document(Revised November 2003).CTD(common technical document)(包括CTD、CTD-Q、CTD-S、CTD-E和eCTD)药品词汇的数据要素和标准5.M4Q (R1) The Common Technical Document for the Registration ofPharmaceuticals for Human Use: Quality (Edited with Numbering and Section Header Changes, September 2002)6.M4S (R2) The Common Technical Document for the Registration ofPharmaceuticals for Human Use: Safety (Edited with Numbering and SectionHeader Changes, September 2002)7.M4E (R1) The Common Technical Document for the Registration ofPharmaceuticals for Human Use: Efficacy (Edited with Numbering and Section Header Changes, September 2002)8.M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities inPharmaceuticals to Limit Potential Carcinogenic Risk Reference:1. 《ICH 药品注册的国际要求》2. /doc/d6990802.html,3./doc/d6990802.html,/health/Health/yx/yao/20 07-08-07/6326.html。

临床研究缩写

临床研究缩写
世界卫生组织
WHO-ICDRA
WHO International Conference of Drug Regulatory Authorities
WHO国际药品管理当局会议
药物临床试验英文缩写
英文全称
中文全称
Accuracy
准确度
Active control,AC
阳性对照 活性对照
Adverse medical events
知情同意书
ICH
International Conference on Harmonization
国际协调会议
IDM
Independent Data Monitoring
独立数据监察
IDMC
Independent Data Monitoring Committee
独立数据监察委员会
IEC
Independent Ethics Committee
独立伦理委员会
IND
Investigational New Drug
新药临床研究
IRB
Institutional Review Board
机构审查委员会
IVD
In Vitro Diagnostic
体外诊断
IVRS
Interactive Voice Response System
互动语音应答系统
MA
Marketing Approval/Authorization
不良医学事件
Adverse reaction
药物不良反应
Alb
白蛋白
ALD(Approximate Lethal Dose)
近似致死剂量
ALP
碱性磷酸酶

火龙罐疗法治疗脾肾阳虚型慢性疲劳综合征的临床观察

火龙罐疗法治疗脾肾阳虚型慢性疲劳综合征的临床观察

火龙罐疗法治疗脾肾阳虚型慢性疲劳综合征的临床观察*郑衍庆① 徐凤宜① 叶焕卿① 【摘要】 目的:观察火龙罐疗法对脾肾阳虚型慢性疲劳综合征的临床疗效、心理状态及生活质量的影响。

方法:将2022年6月—2023年1月在佛山市中医院三水医院治未病科门诊就诊的70例慢性疲劳综合征(脾肾阳虚型)患者按随机数字表法分为对照组和观察组,各35例。

对照组单纯给予生活方式指导,观察组在对照组的基础上再给予火龙罐疗法治疗,每周2次,4周为1个疗程。

治疗前后进行疲劳量表(FS-14)、躯体及心理健康报告(SPHERE)、抑郁自评量表(SDS)、中医症状分级量化表评判,治疗后进行临床效果评估。

结果:治疗后,观察组FS-14、SPHERE及SDS评分分别为(4.85±0.55)、(11.60±2.95)、(50.40±3.08)分,均明显低于治疗前[(10.18±1.44)、(25.99±4.28)、(57.38±3.64)分]及对照组[(6.42±1.02)、(18.73±3.57)、(54.86±2.44)分](P<0.05)。

治疗后,观察组畏寒肢冷、倦怠乏力、少气懒言、食少纳呆、腰酸膝软、脘腹胀满评分分别为(1.25±0.42)、(1.43±0.43)、(1.32±0.36)、(1.18±0.43)、(0.63±0.30)、(0.71±0.34)分,均明显低于治疗前[(4.28±0.54)、(4.25±0.61)、(4.20±0.54)、(4.24±0.57)、(2.18±0.53)、(2.18±0.38)分]及对照组[(2.15±0.40)、(2.16±0.45)、(1.90±0.33)、(1.88±0.40)、(1.14±0.38)、(1.15±0.36)分],差异均有统计学意义(P<0.05);治疗后,两组腰部冷痛、大便不实评分均明显低于治疗前,差异均有统计学意义(P<0.05),观察组上述评分与对照组相比,差异均无统计学意义(P>0.05)。

2023年中考英语热点时文阅读08 感动中国人物

2023年中考英语热点时文阅读08 感动中国人物

2023年中考英语新热点时文阅读-感动中国人物01(2022·山东菏泽·中考真题)The moment that Jiang Mengnan received the award of Person Touching China for 2021, she said she most wanted to express her thanks to her parents. She was chosen on March 3, 2022 to receive the award given on CCTV, which chooses 10 models nationwide every year who spread positive energy(正能量).Born in 1992, Jiang’s world has been silent since she was 6 months old, when medicine she was given completely hurt her hearing. When she was a very young child, her parents began teaching her to read lips (嘴唇). They also taught her how to make sounds by putting her hands on their throats. It was very slow and hard, but her parents never gave up and Jiang learned to speak.When she was old enough, Jiang wan accepted in a normal primary school, not a special school for the disabled. It was difficult at first. During lessons, teachers would often write on the blackboard with their backs to the students, so Jiang missed much of what the teachers said. She had to copy down everything on the blackboard and study alone after class to keep up with her classmates.Her strong willpower(意志力)made her a top student. In 2011, she achieved a very high score on the national college entrance exam and got into Jilin University. After graduating in 2015, she started a further degree at the same university. In 2018, she was accepted as a PhD(博士学位)student at Tsinghua University’s School of Life Sciences.“I’m always grateful for the respect I received from my parents, teachers and friends,” she said. “Theynever give me special attention for my imperfection, which means I’ve never seen myself as different from anyone else.” In the future, she wants to continue scientific research and contribute(贡献)her values to solving problems of life and health.1.Why was the award of Person Touching China given to Jiang Mengnan?A.She did a lot of things for CCTV.B.Her parents regarded her as a model.C.She spread positive energy to people.2.What happened to Jiang Mengnan when she was a baby?A.She lost her hearing.B.Her parents left her.C.She hurt her eyes.3.What does Jiang Mengnan want to do in the future?A.Continue her higher education.B.Solve problems of life and health.C.Build a special school for the disabled.4.What can we learn from Jiang Mengnan?A.Education can bring success.B.Love can overcome difficulties.C.Strong willpower is the key to success.02(2022·福建师范大学附属中学初中部二模)Touching China 2021 Annual People Award Ceremony was held and ten inspirational role models were awarded for their moving stories and great contributions to the society. Here are three people from the list.5.How many role models were awarded in the ceremony?A.Three.B.Five.C.Ten.D.Thirteen.6.Which of the following statements is TRUE?A.Yang Zhenning had no difficulty returning to China from the US.B.Yang Zhenning taught hundreds of Chinese scholars in the US.C.Su Bingtian was the first Chinese sprinter to compete in the Olympic Games.D.Su Bingtian was the only athlete who was nominated on the list.7.What is Jiang Mengnan?A.A foreign scholar.B.A famous athlete.C.A disabled physicist.D.A deaf PhD student.8.What do the three people have in common?A.They have work hard for themselves.B.They have overcome many difficulties. C.They have helped many students.D.They are all in good health.9.We can read this article in a(n) ________.A.novel B.magazine C.travel book D.science book03(2022·河南三门峡·八年级期末)Do you know Su Bingtian? He is a Chinese runner. He was born in Zhongshan City, Guangdong Province on August 20th, 1989.Known as China’s fastest man, Su Bingtian made history and brought an unforgettable moment to the world in the summer of 2021. On Aug 1, Su set a new record of 9. 83 seconds at the Tokyo Olympics Men’s 100m semifinals (半决赛), which made him the first Chinese runner to enter the event’s final round.For a long time, some people thought that Asian people were not physically built for sprinting (短跑). Su’s success shows it’s not true.However, it was not easy for Su to succeed. Because of being hurt, Su had to stop running for several years. Later, he came back to the track (跑道) and trained even harder than before.He realized that finishing the semifinal in less than 10 seconds would earn him a chance to enter the final competition. To encourage himself, Su set a personal goal of 9. 89 seconds in 2012. He even made this number his password for his phone and computer. Luckily, his efforts paid off.On March 3rd, 2022, he was honored (授予……荣誉) in annual Touching China awards. “I am so proud of my result. I can write my name into history now and I will work harder and run faster. I hope my performance today will encourage more people.”Now let’s congratulate to Su Bingtian! We hope Su Bingtian will have a better future and good luck to him!10.Why can we say Su Bingtian write his name into history?A.Because he won the gold medal of Tokyo Olympics.B.Because he was the first Chinese runner to enter the Men’s 100m final round of Olympics. C.Because he showed his success to the whole world.D.Because he is the fastest man in the world.11.Which one is the correct order about Su Bingtian?①He was honored in annual Touching China awards.②He set a personal goal of 9. 89 seconds. ③He was born in Zhongshan, Guangdong.④He set a new record of 9. 83 seconds at the Tokyo Olympics Men’s 100m semifinals.A.③②④①B.③①④②C.③④②①D.③②①④12.What’s the meaning of the underlined phrase “paid off” in Para. 5?A.付钱B.还清C.获得回报D.盈利13.What can we learn from Su Bingtian’s story?A.No pains, no gains.B.Failure is the mother of success. C.The early bird catches the worm.D.A good beginning is half done. 14.Where can we most probably find the passage?A.In a storybook.B.In a travel magazine.C.In a health report.D.In a magazine.04(2022·广东广州·九年级专题练习)For the past 20 years, the Touching China annual people award has honored people from all walks of life across the country. They are people who warm our hearts with their actions. On March 3 2022, the 2021 Touching China Award ceremony aired on CCTV. Ten inspirational role models were on the list, Yang Zhenning is one of them. When mentioning the greatest theoretical physicists in the world, Yang Zhenning is a name never to be forgotten.Yang was born on September 22, 1922, in Hefei Anhui, China, and grew up in the peaceful and academical atmosphere of the campus of Tsinghua University. From a young age he had an interest in physics. At the age of 12, Yang showed his great ambition to win a Nobel Prize after being attracted by a book about the unknowns of the universe.With this goal in mind, Yang studied hard. After getting a master’s degree in Tsinghua University in 1944, Yang got the opportunity to further his studies in the United States. There he met another Chinese student, Tsung-dao Lee (李政道), who shared the same interests, and they often discussed the physics issues together.In 1957, the two jointly proposed the theory of parity non-conservation in weak interactions (弱相互作用中宇称不守恒), which made a great contribution to high-energy physics. Once the theory was put forward, it immediately caused a sensation (轰动) in the physics community. Months later, the two won the Nobel Prize in Physics. It let other Chinese people know that Chinese scientists could stand out in the global science community and be on the global frontier (前沿) to compete with their peers.At the Nobel Banquet, Yang also expressed his pride, saying, “I am as proud of my Chinese heritage and background as I am devoted to modern science, a part of human civilization of Western origin.” No matter where he has been, Yang Zhenning has always had his motherland in mind.However, the frozen Sino-US relationship prevented Chinese scientists who obtained (获得) doctoral degrees from the US like Yang from returning to China. In 1971, Yang finally got the chance to return to China for a visit. Later, to support domestic education, Yang sold a mansion in the US, donating all the money to Tsinghua University. In 2003, Yang returned to China and also taught at Tsinghua. Under his influence, many overseas Chinese also returned to China to make contributions, such as Turing Award winner Yao Qizhi, physicist Wu Xiaogang, mathematician Zhang Shouwu.15.Which of the following statements is wrong?A.Yang Zhenning knew Tsung-dao Lee in Tsinghua University and got the Nobel Prize together. B.Yang Zhenning takes pride in owning Chinese background.C.Yang Zhenning couldn’t return his motherland because of the Sino-US relationship. 16.What does the underlined word mean?A.站出来B.表现C.站起来17.What’s the best title for this article?A.Yang Zhenning’s love to his country.B.Yang Zhenning’s influence.C.Yang Zhenning-one of the 2021 Touching China annual people.18.Which of the following best shows the structure of the passage? (P1=Paragraph 1) A.B.C.05(2022·广东·二模)请阅读下面这篇文章,在所给的每个空格中填入一个形式正确、意义相符的单词。

1981-1983年美国艾滋病应对的历史考察及思考

1981-1983年美国艾滋病应对的历史考察及思考

D O I:10.13419/ki.aids.2021.05.09•论著•1981 —1983年美国艾滋病应对的历史考察及思考步凯,张大庆(北京大学医学人文学院/北京大学科学技术与医学史系,北京100191)摘要:目的考察1981 — 1983年间美国艾滋病流行初期的疾病应对情况,分析总结该时期疾病应对的进展与特征。

方法搜集、查阅该时期相关学术文献、媒体报道、听证会档案、历史著作,加以考据,进行归纳、演绎。

结果艾滋病流行早期的应对呈现三方面特征:疾病认知历时良久,临床病例报告发挥关键作用,预防措施面临复杂争议=结论这些特征既反映出疾病认知是逻辑自洽的科学实践活动.也凸显了疾病认定与应对过程中医学、技术与社会的复杂互动,艾滋病防控的历史实践丰富着对疾病的理解,也有助于拓展审视新发传染病的视域,重塑着应对新发传染病的经验。

关键词:艾滋病;疾病史;医学社会史中图分类号:R 512.91 文献标志码:A文章编号:1672-5662(2021)05-0476-05A Historical Investigation and Reflections on the AIDS Response in the United States, 1981-1983 BU Kai, ZHANGDaqing. (The School o f Health Humanities, Peking University/Department o f History o f Science, Technology, andMedicine, Peking University, Beijing 100191, China)C o r r e s p o n d i n g author: Z H A N G Daqing, Email:z h a n g d q@b j m S u p p orted b y Science Popularization Capacity E n h a n c e m e n t Project o f C h i n a Association for Science a n d T e c h n o l o g y (k x y j s202031); 2020Y u R u n Health R e s earch F u n d Project (2020Y R J K-004)Abstract: Objective T o e x a m i n e a n d analyze the disease response during the early stages o f the A I D S e p i d e m i c in the United States b e t w e e n1981 a n d1983 a n d s u m m a r i z e the disease response's progress a n d characteristics during thisperiod. Methods A n extensive review o f relevant a c a d e m i c literature, m e d i a reports, hearing files, a n d historicalwritings f r o m this period w a s c o n d u c t e d to e x a m i n e these materials a n d m a k e generalizations a n d deductions. ResultsT h e early response to the A I D S e p i d e m i c w a s characterized b y three aspects: long-lasting disease perceptions, the criticalrole o f clinical case reports, a n d c o m p l e x controversies in prevention measures. Conclusion T h e s e characteristics reflectthe fact that disease recognition is a logical a n d self-referential scientific practice a n d highlight the c o m p l e x interactionb e t w e e n medicine, technology, a n d society in the process o f disease identification a n d response. T h e historical pattern o fH I V prevention a n d control has enriched the k n o w l e d g e o f diseases, e x p a n d i n g the scope a n d reshaping examination a n dresponse to the e m e r g i n g infectious diseases.Keywords: H I V/A I D S; History o f the disease; Social history o f m e d i c i n e疾病的社会史见证了艾滋病对社会的巨大冲 击1〃以及人类社会的应对进程。

210983501_鱼刺致星座链球菌肝脓肿1例报告

210983501_鱼刺致星座链球菌肝脓肿1例报告

!1IJK!DOI:10.3969/j.issn.1001-5256.2023.03.023鱼刺致星座链球菌肝脓肿1例报告李佳佳,王 鹤,郭继东,王 超,齐文杰首都医科大学附属北京友谊医院感染内科,北京100050通信作者:齐文杰,qi.wenjie@ccmu.edu.cn(ORCID:0000-0002-5716-9670)关键词:肝脓肿;星座链球菌;肠穿孔基金项目:首都卫生发展科研专项项目基金(首发2020-2-2027)Streptococcusconstellatusliverabscesscausedbyfishbone:AcasereportLIJiajia,WANGHe,GUOJidong,WANGChao,QIWenjie.(DepartmentofInfectiousDiseases,BeijingFriendshipHospital,CapitalMedicalUniversity,Beijing100050,China)Correspondingauthor:QIWenjie,qi.wenjie@ccmu.edu.cn(ORCID:0000-0002-5716-9670)Keywords:LiverAbscess;StreptococcusConstellatus;IntestinalPerforationResearchfunding:TheCapitalHealthResearchandDevelopmentofSpecial(2020-2-2027)1 病例资料 患者女性,44岁,主因“间断发热伴腹痛10d”于2022年4月12日收入本院感染内科。

患者10d前受凉后出现发热,体温约37.5℃,伴腹胀便秘,恶心呕吐,自行口服铝碳酸镁咀嚼片后缓解。

7d前无明显诱因再次出现发热,体温最高39.0℃,伴畏寒、寒战,伴咳嗽,干咳,就诊于外院并完善胸部CT(图1)及腹部核磁,提示右肺下叶微小实性结节、肝脓肿,予莫西沙星及克林霉素抗感染治疗3d后症状未见好转,就诊于本院急诊,入院后查腹部B超提示肝内混合回声团7.0cm×5.6cm×5.3cm,肝脓肿可能,予亚胺培南西司他丁钠抗感染治疗1d收入院。

疑川崎病并发严重冠状动脉病变引发的心血管事件1例报告并文献复习

疑川崎病并发严重冠状动脉病变引发的心血管事件1例报告并文献复习

疑川崎病并发严重冠状动脉病变引发的心血管事件1例报告并文献复习高晓音,秦道刚,吕慧敏,蒋树娟,王军,范玲玲聊城市人民医院儿科,山东聊城252000[摘要]川崎病(Kawasaki disease, KD)是一种病因不明的免疫系统异常活化导致的血管炎性综合征。

冠状动脉病变(coronary arterial lesion, CAL)患者如果没有经过有效治疗,其发生率能够达到25%。

患者恢复期阶段疾病损伤仍然持续存在,时间甚至长达数年,不断损害患者的血管健康,增加血栓形成率,诱发心肌梗死等各种缺血性心脏病。

本研究回顾分析1例13岁、因“胸闷、呼吸困难”入院患儿的临床资料,追问病史,同时检索相关文献并进行总结。

患儿心脏冠状动脉CTA提示双侧冠状动脉瘤并右冠血栓形成,心电图示前间壁的心肌缺血,诊断为严重冠状动脉病变,结合既往病史,考虑患儿胸闷、呼吸困难为表现的心血管事件的发生与可能幼时川崎病并发的严重冠状动脉病变相关。

[关键词]冠状动脉瘤;血栓;冠状动脉病变;64层冠状动脉CTA川崎病[中图分类号]R4 [文献标识码]A [文章编号]2096-1782(2023)08(b)-0140-05A Case Report of a Cardiovascular Event Caused by Suspected Kawasaki Disease Complicated with Severe Coronary Artery Disease and Literature ReviewGAO Xiaoyin, QIN Daogang, LYU Huimin, JIANG Shujuan, WANG Jun, FAN LinglingDepartment of Pediatrics, Liaocheng People′s Hospital, Liaocheng, Shandong Province, 252000 China[Abstract] Kawasaki disease (KD) is a vasculitic syndrome caused by abnormal activation of the immune system of unknown etiology. Without effective arterial therapy, the incidence of coronary artery disease (CAL) can reach 25%. In the recovery stage, the disease damage still persists, even for several years, which continuously damages the blood ves⁃sel health of patients, increases the rate of thrombosis, and induces various ischemic heart diseases such as myocar⁃dial infarction. This study reviewed and analyzed the clinical data of a 13-year-old child admitted to hospital due to "chest tightness and dyspnea", inquired the medical history, searched the relevant literature and made a summary. CTA indicated bilateral coronary aneurysms and right coronary thrombosis in the patient, and electrocardiogram showed myocardial ischemia in the anterior space wall, indicating severe coronary artery disease. Combined with previ⁃ous medical history, it was considered that the occurrence of cardiovascular events manifested by chest tightness and dyspnea in children was related to the possible severe coronary artery lesions complicated with Kawasaki disease in childhood.[Key words] Coronary aneurysm; Blood clot; Coronary artery disease; 64-layer coronary artery CTA Kawasaki disease川崎病(kawasaki disease, KD)属于病因不明的免疫系统异常活化导致的血管炎性综合征[1]。

核酸检测阳性英文报告

核酸检测阳性英文报告

核酸检测阳性英文报告The following is a positive report for a nucleic acid (COVID-19) test:Patient Information:- Name: [Patient Name]- Age: [Patient Age]- Gender: [Patient Gender]- Test Date: [Date]Test Result:- Test Type: Nucleic Acid Amplification Test (NAAT) for COVID-19- Test Result: PositiveInterpretation and Discussion:The nucleic acid test conducted on [Patient Name] on [Date] has yielded a positive result for COVID-19. This indicates the presence of the SARS-CoV-2 virus in the patient's body. It is important to note that a positive test result does not necessarily mean that the patient is experiencing symptoms or is contagious at the time of testing.It is advised that the patient and their healthcare provider carefully review and follow the recommendations provided by the responsible health authorities regarding quarantine, self-isolation, and further medical care. These measures are critical to preventing the spread of the virus to others and to ensure the well-being of the patient.It is important to understand that false negatives or positives can occur in any laboratory test. However, considering the high specificity and sensitivity of nucleic acid tests, a positive result is generally indicative of an ongoing or recent infection with SARS-CoV-2.Treatment and Recommended Actions:Based on the positive result obtained from this nucleic acid test, it is crucial for the patient to self-isolate and minimize contact with others to prevent the potential spread of the virus. The responsible health authorities should be notified immediately to provide appropriate guidance on further testing, monitoring, treatment, and preventive measures.Follow-up testing may be recommended to confirm the diagnosis and monitor the progression or resolution of the infection. It is important for the patient to closely follow their healthcare provider's instructions and advice regarding self-care, symptom management, and treatment options.It is important to remain aware of the latest guidelines and recommendations provided by local health authorities in order to stay updated on the most effective preventive measures and management strategies for COVID-19.Conclusion:The nucleic acid test performed on [Patient Name] indicates a positive result for COVID-19, suggesting the presence of the SARS-CoV-2 virus. The patient should adhere to guidelines provided by health authorities, including self-isolation, monitoringsymptoms, and seeking appropriate medical care. It is crucial to prioritize the well-being of the patient and to prevent the spread of the virus within the community.。

Concord介绍

Concord介绍

OneClick –提供根 提供根 本原因, 本原因,快速解决 问题. 问题.
报警管理器 – 统一所有报警 网络设备报告
使用情况
趋势 最高的N 最高的 CA 版权所有 ◎copyright broadengate 2008 详细资料 2010/7/6 CA - 网络和语音管理 2008 29
性能是否与平时不一样?
时间不可接受 = 15分钟.
正常的 非重复的
% 利用率
上门限值 基本值 下门限值
时间
时间窗口 = 1 小时
Live Health 学习你的端到端的个性 设置
◎copyright broadengate 2008
= 用户定义
端到端的网络性能管理
实时健康状态 管理主控台 响应管理 服务器监控视图 服务水平报告 网络 QoS 技术
主要模块
eHealth 性能管理
健康报表 端到端 PVC
Network
System & App
Response
Technology Keys
服务可用性 Cisco SA Agent
AIM for Check Point FireWall-1
9

网络资产管理
设备和端口资产报表 参数示例 Device and sub components Vendor Device Type IP Address Firmware Version Last Time Rebooted Last Time Patched Sys Uptime Contact Location MAC Address
◎copyright broadengate 2008

◎copyright broadengate 2008

arrow

arrow

Arrow®AC3 Optimus® Intra-Aortic Balloon PumpIABP performance evolvedThe AC3 Optimus ® Intra-Aortic Balloon Pump is up and running with the push of a button. Set up is fast and easy, guided by visual prompts on the large, high-definition touchscreen — including confirmation that therapy can be initiated. Delivering advanced IABP support to even the most compromised patient has never been so simple.Simplicity, right from the startTouchscreen access to alarm settingsAdjust balloon volume by 0.5cc increments360° viewable illuminating switch indicates pump isalarming and the priority levelMost IABP functions are controlled with six keysA touch of the waveform accesses signal-related Heart rate with assisted and unassisted hemodynamic values is clearly displayed in separate colorsEnhanced valueBeyond its clinical value, the AC3 Balloon volume Done36.5 cc100%Third-generation AutoPilot ®ModeMore than advanced, approachableA user-friendly design, intuitive interface, and state-of-the-art AutoPilot ® Mode makes the AC3 Optimus ® IABP simple to use. With this powerful combination, Teleflex counterpulsation therapy is more accessible than ever.• Built for ease-of-useSimple, clean design, large display, fewer keys, mobility/portability• Getting started checklistProvides simple and quick confirmation that routine tasks have been completed• TouchscreenAllows for fast and easy interaction. Action barcombines assessment and action in a single location• Therapy Status ReportQuick and easy access to documenting therapy status• GraphicsSimple green, yellow, and red graphics allow for communication of parameter status• Alarm history reportAllows interpretation of alarm history to assess impact on therapyAccess to alarm history allows for quick review of past alarms and the ability to assess repeated alarms.Key actions and assessments made easy and accessible:Innovative features from the third-generation AutoPilot ® ModeOne-button summary of patient hemodynamics (response to IABP therapy) and therapy settings. Allows for one key stroke charting, with ability to print reports.DoneAn interactive review of the three step startup and confirmation when the pump is ready to start.FOS (Optional)Start PumpDeflation timing managementAutomated to provide real-time and comprehensive deflation timing.Up to 200 bpmProvides precise and accurate support for patients with severe arrhythmias and heart rates as high as 200 bpm.1Best signal analysisContinuously analyzes up to 6 ECG sources in two trigger modes to identify the optimal trigger.2DoneIntraBeat ™ Timing:An advanced solution for a growing problem1.02.03.04.05.06.07.08.09.010.011.012.013.0AF Cases In United StatesYearP r e v a l e n t N u m b e r o f A F C a s e s i n U .S . (M i l l i o n s )Projected prevalence of diagnosed AF cases in United States 3Timing has shown 98.1% accurately timed beats in severe arrhythmia.To address a growing population of arrhythmic patients 3, the AC3 Optimus ® IABP features IntraBeat ™ Timing. It determines individual AV closure points to provide remarkable accuracy during IABP support, even in patients with severe arrhythmias.1,4,5 The AC3 Optimus ® IABP can help your facility be better equipped for your current and future patient populations.Accurate timing is critical to IABP performance. Early inflationtiming errors can have negative effects on IABP therapy,including a decrease in stroke volume by as much as 20% (+/- -6% to -55%).6 Late deflation is also associated with less-than-desirable hemodynamic responses.5,6The solution? IntraBeat ™ Timing for accurate inflation and AutoPilot ® Mode for controlled deflation timing management. The AC3 Optimus ® IABP makes it easy to track, sense, andadapt to changing conditions without routine clinicianintervention, allowing the clinician to focus on what matters most — the patient.EarlyEarlyIn published literature, conventional timing only showed 4 out of 16 Projected prevalence of diagnosed AF cases in United States from 2010 to 2030, assuming (1) no increase in incidence rate after 2007 (solid line) and (2) a logarithmic growth in AF incidence (line with circles).Immediate support with patented technologyThe AC3 Optimus® IABP is designed to deliver support from the very first beat, increasing the volume of blood while decreasing blood pressure.6,10 Accurate aortic flow and pressure is maintained by two proprietary solutions — Flow Conversion and WAVE® Algorithm.Medical Design ExcellenceAwards competition —the industry’s premierdesign competition.Managing risk with Protective Pumping™ Technology While a larger balloon has been shown to improve augmentation, it does not come without potential risks.7,8,9Compare the pressure within the balloon to the augmented pressure. Protective Pumping ™ Technology, another AC3 Optimus ® IABP exclusive feature, allows for measurement of the balloon within the aortic space to determine proper sizing.Monitoring pressure to optimize balloon sizingReferences:1. Donelli A, Jansen JRC, Hoeksel B, et al. Performance of a real-time dicrotic notch detection and prediction algorithm in arrhythmic human aortic pressure signals. J Clin Monit.2002;17(3-4):181-185. Study sponsored by Teleflex.2. Torracca, L. Overcoming electro-surgical inference in IABP therapy with the combined use of AutoPilot and FiberOptix IAB sensor signal. 2007. (case report, data on file).Study sponsored by Teleflex.3. Susan Colilla, PhD, MPHa, Ann Crow, MLSb, et al. Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population. Am J Cardiol.2013 Oct 15;112(8):1142-74. Hoeksel S, Jansen J, Blom J, & Schreuder J,. Detection of dicrotic notch in arterial pressure signals. J Clin Monit. 1997;13(5),309-316. Study sponsored by Teleflex. Dr. Schreuderwas formerly a paid consultant of the study sponsor.5. Schreuder J, Castiglioni A, Donelli A, et al. Automatic intraaortic balloon pump timing using an intra beat dicrotic notch prediction algorithm. Ann Thorac Surg.2005;79(3):1017-1022. Study sponsored by Teleflex. Dr. Schreuder was formerly a paid consultant of the study sponsor.6. Schreuder J, Maisano F, Donelli A, et al. Beat-to-beat effects of intra-aortic balloon pump timing on left ventricular performance in patients with low ejection fraction. AnnThorac Surg. 2005;79(3):872-880. Study sponsored by Teleflex. Dr. Schreuder was formerly a paid consultant of the study sponsor.7. Parissis et al. Intra aortic balloon pump: literature review of risk factors related to complications of the intraaortic balloon pump. Journal of Cardiothoracic Surgery 2011, 6:1478. Young-Seok Cho, Cheong Lim, et al. Should We Consider the Ethnic Difference in Selecting Size of Intraaortic Balloon by Commercial Guideline?ASAIO Journal 20099. Ardawan Julian Rastan, MD, PhD; Eugen Tillmann, MD et al. Visceral Arterial Compromise During Intra-Aortic Balloon Counterpulsation Therapy. Circulation.2010;122[suppl 1]:S92–S9910. Parissis, H, Soo, A, Leotsinidis, M, and Dougenis, D, A statistical model that predicts the length from the left subclavian artery to the celiac axis; towards accurate intraaortic balloon sizing. Journal of Cardiothoracic Surgery. 2011, 6:95.11. Data on fileTeleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the under-standing that what we do every day makes a difference. For more information, please visit .Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rüsch®, and Weck® – trusted brands united by a common sense of purpose.Corporate OfficePhone +1 610 225 6800, 550 E. Swedesford Road, Suite 400, Wayne, PA 19087, USARegional OfficesUnited States:Phone+19195448000,TollFree8662466990,***************,3015CarringtonMillBoulevard, Morrisville, NC 27560, USALatin America:Phone+19194334999,******************,3015CarringtonMillBoulevard,Morrisville,NC27560,USA International:Phone+353(0)906460800,************************,TeleflexMedicalEuropeLtd.,IDA Business and Technology Park, Dublin Road, Athlone, Co Westmeath, IrelandFor more information, please visit .Teleflex, the Teleflex logo, Arrow, AC3 Optimus, AutoPilot, IntraBeat, Protective Pumping and WAVE are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.Information in this material is not a substitute for the product Instructions for Use. Not all products may be available in all countries. Please contact your local representative. Revised: 08/2019.© 2019 Teleflex Incorporated. All rights reserved. MC-005536 · Rev 0.1。

ATEX产品认证证书说明书

ATEX产品认证证书说明书

1. EU-TYPE EXAMINATION CERTIFICATE2. Equipment or Protective System Intended for use in Potentially Explosive AtmospheresDirective 2014/34/EU3. EU-Type Examination Certificate Number: ITS08ATEX15994X - Issue 24. Product:MS41 Series Magnetic Switch5. Manufacturer:ABB Inc.6. Address: 125 East County Line RdWarminster, PA 18974USA7. This product and any acceptable variation thereto is specified in the schedule to this certificate and thedocuments therein referred to.8. Intertek Testing and Certification Limited, Notified Body number 0359 in accordance with Article 17 ofDirective 2014/34/EU of the European Parliament and of the Council dated 26 February 2014, certifies that the product has been found to comply with the Essential Health and Safety Requirements relating to the design and construction of products intended for use in potentially explosive atmospheres given in Annex II to the Directive.The examination and test results are recorded in confidential Intertek Report Ref 103106600CRT-002A, 103106600CRT-002B, and 103106600CRT-002C all dated 2017-07-19.9. Compliance with the Essential Health and Safety Requirements has been assured by compliance withEN 60079-0:2012, EN 60079-1:2014, EN 60079-31:2012 except in respect of those requirements referred to at item 16 of the Schedule.10. If the sign “X” is placed after the certificate number, it indicates that the product is subject to SpecificConditions of Safe Use specified in the Schedule to this certificate.11. This EU-Type Examination Certificate relates only to the design and construction of the specifiedproduct. Further requirements of the Directive apply to the manufacturing process and supply of this product. These are not covered by this certificate.12. The marking of the product shall include the following:II 2 G Ex db IIC T* GbII 2 D Ex tb IIIC T* Db-50°C ≤ Ta ≤ 78°CIntertek Testing & Certification Limited Todd L. Relyea Intertek House, Cleeve Road, Leatherhead, Surrey, KT22 7SB Certification Officer Tel: +44 (0)1372 370900 Fax: +44 (0)1372 37097728 August 2017 Registered No 3272281 Registered Office: Academy Place, 1-9 Brook Street, Brentwood, Essex,CM14 5NQ.Page 1 of 4This certificate may only be reproduced in its entirety and without any change, schedule included and is subject to Intertek Testing and Certification’s Conditions for Granting Certification.RFT-EU-NB-OP-23k1 June 29, 2016SCHEDULEEU-TYPE EXAMINATION CERTIFICATE NUMBER ITS08ATEX15994X - Issue 213. Description of Equipment or Protective SystemThe MS41 level switch is a magnetically actuated double pole, double throw switch that is housedinside a flameproof enclosure.The MS41 comprises a 316L stainless steel body formed into two sections by a dividing wall that is an integral part of the enclosure. One section contains a pivoting magnetic rocker which activates twomicro switches and the other section contains a printed circuit board with screw terminals mounted forexternal connections. The dividing wall is penetrated by six hermetically sealed glass feed-throughconnectors to allow connections between the switches and the external circuit board.The end of the body section containing the rocker and switches is enclosed by a welded stainless-steel endcap. The terminal section is enclosed by a threaded endcap to allow for access to the wiringterminals during installation. The wiring enters via a ¾” NPT entry. The body has an In gress protection level of IP67.Options for temperature codes:T6/T80°C for process temperatures up to 78°CT5/T95°C for process temperatures up to 93°CT4/T130°C for process temperatures up to 128°CT3/T195°C for process temperatures up to 193°CT2/T290°C for process temperatures up to 288°CT1/T440°C for process temperatures up to 438°CModel number matrix:MS41.a.b.E2 where:a: Mounting:S –Standard; Process temperatures up to 149°CIH –Includes Switch Insulation pad; Process temperatures up to 315°CRD –Includes rod mount brackets for use with insulated KM26 Magnetic level gauges orST95 seal fluid supply tanks with switch rods; Process temperatures up to 454°C b: Electrical Connection:F7 - ¾” FNPT entry, standardM2 - Inclusion of an Ex db IIC Gb, Ex tb IIIC Db IP67 certified ¾ NPT to M20 Adapter c: Approvals:E2 –ATEX / IECEx Flameproof Housing14. Report NumberIntertek Report Ref 103106600CRT-002A, 103106600CRT-002B, and 103106600CRT-002C all dated 2017-07-19.Page 2 of 4This Certificate is the property of Intertek Testing and Certification Ltd and is subject to Intertek Testing and Certification’s Conditions for Granting Certification RFT-EU-NB-OP-23k1 June 29, 2016SCHEDULEEU-TYPE EXAMINATION CERTIFICATE NUMBER ITS08ATEX15994X - Issue 2Page 3 of 4This Certificate is the property of Intertek Testing and Certification Ltd and is subject to Intertek Testing andCertification’s Conditions for Granting Certification RFT-EU-NB-OP-23k1 June 29, 201615. Special Conditions of Certification(a). Specific Conditions of Safe Use• Entry to the device must be made by suitably certified Ex db IIC Gb and Ex tb IIIC Db IP67entry devices.• Process temperatures may cause temperatures at the entry and branching points to beabove 80°C.(b). Conditions of Manufacture - Routine Tests• Routine overpressure test on metallic enclosure without hermetically sealed feed- throughsin place of 19.1 Bar.…16. Essential Health and Safety Requirements (EHSRs)The relevant Essential Health and Safety Requirements (EHSRs) have been identified and assessed in Intertek Report Ref 103106600CRT-002A, 103106600CRT-002B, and 103106600CRT-002C all dated 2017-07-19. 17. Drawings and DocumentsTitle:Drawing No.: Rev. Level: Date: MS41 SWITCH CERTIFICATION DRAWING AND OPTIONSMS41-0062-1 E 02/05/16 *Operating instruction manual OI/MS41-EN Rev. E MS41 Magnetic level gauge switchOI/MS41-ENE08/2017*MS41 SERIES ATEX & IECEx FLAMEPROOF NAMEPLATE E2 OPTION TAG0032 G08/11/1718. Details of Certificate Changes Issue 2Change Address: from: 17100 Manchac Park Lane Baton Rouge, LA 70817 USAto:125 East County Line Rd; Warminster, PA 18974; USA。

  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

Understanding Down SyndromeThis is the VOA Special English Health Report.Deep inside each cell in our body is all the genetic information needed for life. Human genes are normally organized along forty-six chromosomes -- twenty-three from each parent.David Petersohn of Liberty, Missouri, reads with his daughter Darcie, who has Down syndromeBut as a result of a mistake in cell division, some people have three copies of the twenty-first chromosome. There are supposed to be just two.About one in every seven hundred babies has this extra copy. The name for this condition is Down syndrome. A British doctor named John Langdon Down first described it in the eighteen sixties.Republican vice presidential candidate Sarah Palin has a son who was born in April with Down syndrome. The Alaska governor and her husband also have four other children who do not have it.Many babies with Down syndrome have low muscle tone, so they need extra support when they are held. Their heads are smaller than average and they can have unusually shaped ears. Also, their eyes often angle upward.People with Down syndrome often have other conditions. These include problems with their heart and with their breathing and hearing. But a lot of these conditions are treatable.As a result, people with Down syndrome are living longer. In nineteen eighty-three, they lived an average of just twenty-five years. Today the average life expectancy is fifty-six.But that longer life has led to a sad discovery. People with Down syndrome may have an increased risk for Alzheimer's disease at an early age.The National Down Syndrome Society says an estimated twenty-five percent of those thirty-five and older show signs of Alzheimer's.In the general population, this brain-wasting disease is usually not found until people are over the age of sixty-five. It slowly destroys memory, thinking and reasoning skills.Down syndrome is the most common genetic cause of mental retardation. Most people with Down syndrome are mildly to moderately retarded. Many are able to attend regular classes with other students. Later, as adults, many hold jobs and lead independent lives.An estimated three hundred fifty thousand people in the United States have Down syndrome. There are tests that can be done to look for it during pregnancy.The risk of Down syndrome is higher for older mothers. The rate for those under thirty is one in one thousand births. In women age forty-four, like Sarah Palin, that number is one in thirty-five.And that's the VOA Special English Health Report, written by Caty Weaver. I'm Steve Ember.Teenagers and PregnancyThis is the VOA Special English Health Report.More than seven hundred thousand teenagers a year get pregnant in the United States. The teen pregnancy rate has fallen thirty-eight percent since the early nineteen nineties. And the National Campaign to Prevent Teen and Unplanned Pregnancy says the teen birth rate has fallen by almost as much. Six out of ten pregnant teenagers in two thousand six gave birth.The nonprofit campaign says these changes have been driven by decreases in sexual activity and increases in contraceptive use. But it points to recent findings that reductions in teen sex and increases in contraceptive use have leveled off. And the teen birth rate is rising for the first time in fifteen years.Last week, many Americans talked about the news that the seventeen-year-old daughter of Sarah Palin is pregnant and will get married. Sarah Palin is the governor of Alaska and the Republican nominee for vice president. Campaign officials said the family released a statement because of claims on the Internet that the candidate's baby son was really her daughter's baby.But there have been other reasons why teen pregnancy has been more of a subject of national discussion lately.The movie "Juno" came out last December. A teenager gets pregnant and decides to have the baby and give it up for adoption. This comedy about a serious subject won an Academy Award.And this past June, Jamie Lynn Spears gave birth. The TV star and sister of Britney Spears was sixteen when she got pregnant. Many parents of her young fans were not happy to have to discuss it.Eight out of ten pregnancies in teenagers are unplanned, compared to half of all pregnancies nationally.A two thousand one UNICEF report on teenage births in rich nations showed that the United States had the highest rate. But, as a New York Times columnist just noted, the United States did not have the highest rate of sexually active teens. A few others had higher rates. Denmark had the highest. Yet its teen birth and teen abortion rates were much lower than America's.Part of the debate over what to do about teen pregnancy is how to deal with sex education. Some people argue for an expansion of "abstinence-only" programs. These center on the message that young people should not have sex until marriage. Other people argue that while this may be a good message to teach, it should not be the only one taught in schools.And that's the VOA Special English Health Report, written by Caty Weaver. I'm Steve Ember.9.17New Findings on Children and Mental IllnessThis the VOA Special English Health Report.People who are schizophrenic sometimes hear voices or see things that are not real.They might believe other people want to hurt them. They can become fearful and socially withdrawn.Schizophrenia is explained on the National Institute of Mental Health Web site as a brain disorder that is severe and disabling. It is also chronic, meaning long term.The disorder usually appears in males in their late teens or early twenties and in females in their twenties or thirties. Experts say it rarely appears in children, but when it does, it generally affects them more severely than adults.Children with schizophrenia are often treated with "second-generation" antipsychotic drugs. But do these costly newer drugs work better than older ones that cost less? The National Institute of Mental Health recently paid for a study by four universities in the United States. The research teams found that the answer was no.They studied one hundred nineteen people between the ages of eight and nineteen. The patients were observed over an eight-week period. Some received risperidone or olanzapine, two newer drugs. Others received a first-generation antipsychotic drug, molindone.The researchers found that all of the patients experienced about the same improvement. But the risperidone and olanzapine caused serious weight gain.In fact, the institute cancelled the olanzapine research because the patients who took it gained an average of almost six kilograms. The concern was that the weight gain could lead to diabetes.The study appeared in the American Journal of Psychiatry.Past studies have shown that children born to older fathers have a higher risk of schizophrenia as well as autism. Now, scientists are finding evidence of a similar link for bipolar disorder. This disorder is marked by periods of extremes in mood and behavior. It was formerly called manic depression.A new study in Sweden involved more than thirteen thousand patients with bipolar disorder. Researchers compared them to similar people of the same age and sex who did not have the disorder.The study found that fathers fifty-five and older were one and a third times more likely to have a bipolar child than fathers twenty to twenty-four. The scientists say the reason could be that older sperm is more likely to cause genetic abnormalities. The findings are in this month's Archives of General Psychiatry.And that's the VOA Special English Health Report, written by Caty Weaver. I'm Steve Ember.9.25New Findings Add to Health Concerns About a Chemical in PlasticsThis is the VOA Special English Health Report.Bisphenol A is a chemical widely used to make hard, polycarbonate plastic. Food storage containers, reusable water bottles and baby bottles are among the many different products that may contain BPA. BPA is also commonly used in protective coverings inside metal food and drink cans.People can swallow small amounts of BPA as they eat or drink. An industry Web site says more than forty years of safety research shows that products made withbisphenol A are safe.But others question the safety of BPA. Now, a large study has linked it to diabetes and heart disease in adults.Researchers divided almost one thousand five hundred American adults into four groups based on BPA levels in their urine. All the levels were within the limits considered safe by the United States Food and Drug Administration. Yet the study found that the highest group was more than twice as likely as the lowest group to have heart disease or diabetes, or both.The Food and Drug Administration and chemical industry officials said the study does not show that bisphenol A caused the diseases. The researcher who led the study, David Melzer at England's University of Exeter, agrees. He says the findings must be reproduced and that other studies are also needed.But he also says that if BPA is a cause of these conditions, then just reducing contact with it might prevent some cases. The study appeared last week in the Journal of the American Medical Association.Earlier this month, United States government scientists from the National Toxicology Program released a final report on BPA. They found that the chemical is of "some concern" for effects on development of the prostate gland and brain in fetuses, infants and children. They made the same finding for behavioral effects.The scientists based their findings mostly on studies of laboratory animals. Even so, the program director said "the possibility that BPA may affect human development cannot be dismissed."In April, Canada became the first country to propose a ban on plastic baby bottles that contain BPA. The government has said it will publish its final decision by October eighteenth.Some plastic goods are now being marketed as BPA-free. But some people wonder whether any other chemicals that might take its place are any better.And that's the VOA Special English Health Report, written by Caty Weaver. I'm Jim Tedder.。

相关文档
最新文档